Eli Lilly and Company– tag –
-
Resilience and Eli Lilly Expand Strategic Partnership with $750M Investment to Boost U.S. Manufactured Medicine Supply
Resilience USA Overview Resilience and Eli Lilly and Company have expanded their strategic partnership with a significant $750 million investment aimed at increasing the supply of critical medicines manufactured in the U.S. This investme... -
Eli Lilly’s Retatrutide Emerges as Most Powerful Obesity Drug Yet, Achieves Five Consecutive Positive Phase 3 Readouts in TRIUMPH Program
Drug Discovery News USA Overview Eli Lilly's triple agonist retatrutide has shown positive results in metabolic disease, positioning it as a powerful obesity drug. The company has achieved five consecutive positive Phase 3 readouts acros... -
Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission
BioPharma Dive USA Overview Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average bod... -
Eli Lilly Acquires Kelonia and Orna Therapeutics as Investment in In Vivo Cell Therapies Surges, Aiming to Reduce Treatment Burden and Manufacturing Costs
DCAT Value Chain Insights USA Overview In vivo cell therapies, where the patient's body becomes the manufacturing site for cells like CAR T cells, are attracting substantial biopharmaceutical investment due to their potential to reduce t... -
Eli Lilly’s Triple G-Agonist Retatrutide Succeeds in Two More Phase III Trials for Obesity and Type 2 Diabetes
GlobalData USA Overview Eli Lilly's GLP-1/GIP/Glucagon (GCG) triple receptor agonist, retatrutide, met primary endpoints in two additional Phase III trials (TRIUMPH-2 and TRIUMPH-3) for type 2 diabetes and obesity patients with establish... -
Eli Lilly Acquires AtaiBeckley to Accelerate Phase III Development of BPL-003 for Treatment-Resistant Depression and Mental Health
Eli Lilly and Company USA Overview Eli Lilly announced the acquisition of AtaiBeckley to accelerate the development of therapies for treatment-resistant depression (TRD) and other mental health conditions. AtaiBeckley's lead candidate, B... -
Obesity Treatment Advances: Foundayo and Oral Wegovy Lead Oral GLP-1 Market, Retatrutide Shows Significant Weight Loss in Phase II
GoodRx Health USA Overview The obesity therapeutics market is rapidly evolving, with Foundayo (orforglipron) and oral Wegovy driving the oral GLP-1 segment. Foundayo, FDA-approved on April 1, 2026, offers the novel advantage of being tak... -
Novartis Reverses ADC Holdout with $1.5B Myricx Deal Amid Sustained M&A Boom in ADC Market
Fierce Biotech USA Overview Novartis, previously hesitant about Antibody-Drug Conjugates (ADCs), has committed up to $1.5 billion to Myricx Bio, signaling a strategic shift into the burgeoning ADC market. This move follows a series of hi... -
Eli Lilly Acquires Kelonia Therapeutics for $7 Billion, Bolstering Gene Therapy with In Vivo CAR-T Generation Technology
DCAT Value Chain Insights USA Overview Eli Lilly announced the acquisition of Kelonia Therapeutics, a clinical-stage biopharma specializing in in vivo gene delivery, for $7 billion, including $3.25 billion upfront. Kelonia's "iGPS" techn... -
FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors, Expanding Patient Access
FDA USA Overview On July 14, 2026, the FDA granted traditional approval to Eli Lilly and Company's Retevmo (selpercatinib) for patients aged two years and older with locally advanced or metastatic RET fusion-positive solid tumors that ha...
